Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Prostate Cancer
Advertisement
Latest News
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
The panel concludes with a discussion on the early use of PARP inhibitors in patients with DNA repair mutations like BRCA1/2.
The panel delves into how de novo metastases signal more aggressive prostate cancer biology.
The panel weighs the role of next-generation sequencing and emphasizes how SPOP, TP53, and RB1 guide treatment decisions.
The panel considers the evolving management of oligometastatic prostate cancer, highlighting the role of MDT.
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Updated phase 3 study assesses long-term outcomes of adjuvant pembrolizumab in patients with ccRCC at risk of recurrence.
Tumor microenvironment and circulating factors studied for potential links to treatment response in aRCC.
Advertisement
Advertisement
Trending
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Pathologic response and IHC post-treatment influx of CD8+CD39+ TILs are linked with prolonged DFS after neoadjuvant therapy.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.